Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 2,401–2,500 of 4,628
Li, Y., Yang, H., Zhao, X., Zhao, X., Quan, J., Wang, L., Ma, E., & Ma, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116608 · Cited by 9
Connective Tissue Disease Associated Interstitial Lung Disease
Matson, S. M., & Demoruelle, M. K. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.03.001 · Cited by 11
Treatment of acute exacerbations of interstitial lung diseases with corticosteroids: Evidence?
Hung, C. F., & Raghu, G. (2024) · Respirology · doi:10.1111/resp.14788 · Cited by 10
Self-citationGeorge, P. M., Rennison-Jones, C., Benvenuti, G., Sifostratoudaki, A., Ottink, F. A., Bou-Zeid, W., Ledda, R. E., Kadir, R. F. A., Johari, B., Fernandez, C., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00570-2024 · Cited by 17
Kim, M. J., Nathan, S. D., Kim, H. H., & Kim, H. C. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241275329 · Cited by 9
Ding, K. L., Smith, C., Seedorf, G., & Abman, S. H. (2024) · Pediatric Research · doi:10.1038/s41390-024-03562-0 · Cited by 14
Suzuki, Y. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.12.009 · Cited by 13
Lu, J., Sun, L., Mei, D., Liu, C., Xia, T., Li, J., & Meng, H. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102778 · Cited by 12
Idiopathic Pulmonary Fibrosis, Today and Tomorrow: Certainties and New Therapeutic Horizons
Giulianelli, G., Cocconcelli, E., Fiorentù, G., Bernardinello, N., Balestro, E., & Spagnolo, P. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00296-0 · Cited by 18
Hughes, D., Prestle, J., Zippel, N., McFetridge, S., Szczepan, M., Neubauer, H., Xu, H., & Chen, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157131 · Cited by 15
“Nintedanib has been used to treat idiopathic pulmonary fibrosis since 2014 [27,33].”
Therapeutic targets in fibrotic pathways
Lear, T., & Chen, B. B. (2016) · Cytokine · doi:10.1016/j.cyto.2016.09.008 · Cited by 9
Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
Shimomura, I., Abe, M., Yu, L., Tsushima, K., Sakao, S., Tanabe, N., Ikusaka, M., & Tatsumi, K. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1384-18 · Cited by 10
Imatinib a Tyrosine Kinase Inhibitor: a potential treatment for SARS- COV-2 induced pneumonia
Assaad, H. S., & Assaad-Khalil, S. H. (2020) · Alexandria Journal of Medicine · doi:10.1080/20905068.2020.1778417 · Cited by 12
Identification of Potential Pathogenic Super-Enhancers-Driven Genes in Pulmonary Fibrosis
Li, H., Zhao, C., Li, Z., Yao, K., Zhang, J., Si, W., Liu, X., Jiang, Y. M., & Zhu, M. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.644143 · Cited by 10
Mekhael, O., Naiel, S., Vierhout, M., Hayat, A. I., Revill, S. D., Abed, S., Inman, M. D., Kolb, M. R. J., & Ask, K. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1382-5_21 · Cited by 12
Self-citationNear, A. M., Burudpakdee, C., Viswanathan, S., & Kaila, S. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01768-w · Cited by 10
Improved Radiolytic Stability of a 68Ga-labelled Collagelin Analogue for the Imaging of Fibrosis
Velikyan, I., Rosenström, U., Rosestedt, M., Eriksson, O., & Antoni, G. (2021) · Pharmaceuticals · doi:10.3390/ph14100990 · Cited by 9
van Batenburg, A. A., van Oosterhout, M. F. M., Knoppert, S. N., Kazemier, K. M., van der Vis, J. J., Grutters, J. C., Goldschmeding, R., & van Moorsel, C. H. M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.736485 · Cited by 9
“Since familial disease resembles sIPF, the preferred choices of drugs are antifibrotics pirfenidone and nintedanib (31, 32).”
BackgroundAnan, K., Kataoka, Y., Ichikado, K., Kawamura, K., Johkoh, T., Fujimoto, K., Tobino, K., Tachikawa, R., Ito, H., Nakamura, T., et al. (2022) · Annals of Clinical Epidemiology · doi:10.37737/ace.22008 · Cited by 8
Nagel, D. J., Rackow, A. R., Ku, W.-Y., Bell, T. J., Sime, P. J., & Kottmann, R. M. (2022) · Cells · doi:10.3390/cells11162540 · Cited by 9
Zhan, Z., Wei, Z., Ying, B., Chai, L., Yu, Q., Yu, X., Zhou, L., Wan, C., Fan, L., Huang, J., et al. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.132575 · Cited by 9
CT predictors of outcomes in patients with connective tissue disease and progressive lung fibrosis
Shou, A. Y., & Salvatore, M. M. (2022) · Clinical Imaging · doi:10.1016/j.clinimag.2022.11.022 · Cited by 9
Inoue, Y., Wells, A. U., Song, J. W., Xu, Z., Kitamura, H., Suda, T., Okamoto, M., Müller, H., Coeck, C., Rohr, K. B., et al. (2023) · Respirology · doi:10.1111/resp.14452 · Cited by 10
Self-citationNakshbandi, G., Moor, C. C., Antoniou, K. M., Cottin, V., Hoffmann‐Vold, A., Koemans, E. A., Kreuter, M., Molyneaux, P. L., Wuyts, W. A., & Wijsenbeek, M. S. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02336-4 · Cited by 11
Self-citationClinical Profile of Patients with Idiopathic Pulmonary Fibrosis in Real Life
Morena, D., Fernández, J. R., Campos, C., Castillo, M., López, G., Benavent, M., & Izquierdo-Alonso, J. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041669 · Cited by 12
“These results are in line with previous reports [25,26].”
ResultMakiguchi, T., Tanaka, H., Okudera, K., Taima, K., & Tasaka, S. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-699 · Cited by 9
Han, C. Q., Wang, L., Dong, Z.-Q., Wang, P., Lv, Y., Wang, D., & Hu, L. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-08052-7 · Cited by 11
Deep learning-based prognostication in idiopathic pulmonary fibrosis using chest radiographs
Lee, T., Ahn, S. Y., Kim, J., Park, J. S., Kwon, B. S., Choi, S. M., Goo, J. M., Park, C. M., & Nam, J. G. (2023) · European Radiology · doi:10.1007/s00330-023-10501-w · Cited by 9
Current and Novel Treatment Modalities of Idiopathic Pulmonary Fibrosis
Arshad, M., Athar, Z. M., & Hiba, T. (2024) · Cureus · doi:10.7759/cureus.56140 · Cited by 14
“Nintedanib also reduced the risk of acute exacerbations and disease progression in patients with IPF [28].”
BackgroundIommi, M., Gonnelli, F., Bonifazi, M., Faragalli, A., Mei, F., Pompili, M., Carle, F., & Gesuita, R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13092727 · Cited by 12
“Clinical trials have demonstrated the efficacy of both antifibrotics in reducing the progression of the disease [3,4], although reporting a high frequency of common adverse events (diarrhoea, nausea, vomiting, weight loss), which might lead to a dose reduction, a shift towards the other drug, or…”
BackgroundNew Treatments for Idiopathic Pulmonary Fibrosis: ‘Die Another Day' if Diagnosed Early?
Antoniou, K. M., Symvoulakis, E. K., Anyfantakis, D., et al. (2015) · Respiration · doi:10.1159/000436980 · Cited by 9
Moving stem cell therapy to patients with idiopathic pulmonary fibrosis
Glassberg, M. K., & Toonkel, R. L. (2014) · Respirology · doi:10.1111/resp.12364 · Cited by 9
Honeycomb Lung: Time for a Change
Kradin, R. L. (2015) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0065-sa · Cited by 9
Rubin, A. S., Nascimento, D. Z., Sanchez, L., Watte, G., Holand, A. R. R., Fassbind, D. A., & Camargo, J. J. (2015) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132015000000057 · Cited by 10
Prognostic value of the initial chest high-resolution CT pattern in idiopathic pulmonary fibrosis.
Rouzic, O. L., Bendaoud, S., Chenivesse, C., Rémy, J., & Wallaert, B. (2016) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 10
Broad Therapeutic Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis
Wells, A. U., & Rosas, I. O. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201510-2052ed · Cited by 9
Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis
Cordeiro, C. R., Campos, P., Carvalho, L., Campainha, S., Clemente, S., Figueiredo, L., Jesus, J. M., Marqués, J., Souto-Moura, C., Basto, R. P., et al. (2016) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2016.01.003 · Cited by 19
Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis
Miyamoto, A., Morokawa, N., Takahashi, Y., Ogawa, K., Takeyasu, M., Murase, K., Hanada, S., Uruga, H., Mochizuki, S., Takaya, H., et al. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.5259 · Cited by 9
Acetylcysteine in IPF: the knockout blow?
Wijsenbeek, M. S., & Collard, H. R. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30085-6 · Cited by 9
Self-citationEfficacy study of edaravone and acetylcysteine towards bleomycin-induced rat pulmonary fibrosis.
Yu, W., Tian, L., & Cheng, W. (2015) · Europe PMC (PubMed Central) · Cited by 9
von Suesskind-Schwendi, M., Boxhammer, E., Hirt, S. W., Schreml, S., Schmid, Ç., Wollin, L., & Lehle, K. (2017) · Experimental Lung Research · doi:10.1080/01902148.2017.1354408 · Cited by 13
Idiopathic pulmonary fibrosis: What primary care physicians need to know
Tolle, L. B., Southern, B. D., Culver, D. A., & Horowitz, J. C. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.17018 · Cited by 9
Takeda, T., Takeuchi, M., Saitoh, M., & Takeda, S. (2018) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.245.107 · Cited by 9
Chai, G., Tan, T. C., Lee, Y., Kaw, G. J. L., Kl, C., Lim, Y., Abisheganaden, J. A., & Thong, B. Y. (2019) · Singapore Medical Journal · doi:10.11622/smedj.2019069 · Cited by 11
Discovery of an Orally Bioavailable Pan αv Integrin Inhibitor for Idiopathic Pulmonary Fibrosis
Anderson, N. A., Campos, S., Butler, S., Copley, R. C. B., Duncan, I., Harrison, S., Le, J., Maghames, R., Pastor-Garcia, A., Pritchard, J. M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00962 · Cited by 9
Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
Santermans, E., Ford, P., Kreuter, M., Verbruggen, N., Meyvisch, P., Wuyts, W. A., Brown, K. K., Lederer, D. J., Byrne, A. J., Molyneaux, P. L., et al. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01093-3 · Cited by 8
Self-citationTakeda, T., Kunimatsu, Y., Tani, N., Hashimoto, I., Kurono, Y., & Hirose, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030755 · Cited by 9
Marks-Garber, K., Bdolah‐Abram, T., & Nusair, S. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.05.023 · Cited by 9
The adoption of nintedanib in systemic sclerosis: the SENSCIS study
Bruni, T., & Varone, F. (2020) · Breathe · doi:10.1183/20734735.0005-2020 · Cited by 9
“The two INPULSIS studies clearly showed efficacy of this drug in slowing the rate of functional decline [3].”
BackgroundVainshelboim, B. (2020) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000544 · Cited by 10
Galectin-3 levels are elevated following nintedanib treatment
Shochet, G. E., Pomerantz, A., Shitrit, D., Bardenstein-Wald, B., Ask, K., Surber, M. W., Rabinowicz, N., Levy, Y. M., Benchetrit, S., Edelstein, E., et al. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320968412 · Cited by 9
Antifibrotic drugs for pulmonary sarcoidosis: A treatment in search of an indication
Judson, M. A. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106371 · Cited by 9
Fu, Y., Gong, T., Tsauo, J., Sang, M., Zhao, H., Zhang, X., Li, J., & Li, X. F. (2021) · Surgery · doi:10.1016/j.surg.2021.03.055 · Cited by 10
Unclassifiable, or simply unclassified interstitial lung disease?
O’Callaghan, M., Bonella, F., & McCarthy, C. (2021) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000801 · Cited by 9
An update on interstitial lung disease
Mudawi, D., Heyes, K., Hastings, R., Rivera‐Ortega, P., & Chaudhuri, N. (2021) · British Journal of Hospital Medicine · doi:10.12968/hmed.2020.0556 · Cited by 12
Lacedonia, D., Correale, M., Tricarico, L., Scioscia, G., Stornelli, S. R., Simone, F., Casparrini, M., Brunetti, N. D., & Barbaro, M. P. F. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02883-w · Cited by 11
Cummins, K. A., Bitterman, P. B., Tschumperlin, D. J., & Wood, D. K. (2021) · APL Bioengineering · doi:10.1063/5.0054967 · Cited by 11
Çilli, A., Üzer, F., Sevinç, C., Çoşkun, F., Ursavaş, A., Öner, Ş., & Köse, F. (2021) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2021.102099 · Cited by 10
Todd, N. W., Atamas, S. P., Hines, S. E., Luzina, I. G., Shah, N. G., Britt, E. J., Ghio, A. J., & Galvin, J. R. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2030710 · Cited by 10
Salvi, S. S., Ghorpade, D., Dhoori, S., Dhar, R., Dumra, H. S., Chhajed, P. N., Bhattacharya, P., Rajan, S. K., Talwar, D., Christopher, D. J., et al. (2022) · Lung India · doi:10.4103/lungindia.lungindia_659_21 · Cited by 11
Caveolin-1 peptide regulates p53-microRNA-34a feedback in fibrotic lung fibroblasts
Hogan, T. B., Tiwari, N., Nagaraja, M. R., Shetty, S. K., Fan, L., Shetty, R. R., Bhandary, Y. P., & Shetty, S. (2022) · iScience · doi:10.1016/j.isci.2022.104022 · Cited by 11
Wuyts, W. A., Dahlqvist, C., Slabbynck, H., Schlesser, M., Gusbin, N., Compère, C., Maddens, S., Rizzo, S., Kirchgaessler, K.-U., Bartley, K., et al. (2022) · Pulmonary Therapy · doi:10.1007/s41030-022-00187-8 · Cited by 10
Dhooria, S., Maturu, V. N., Talwar, D., Kumar, S., Handa, A., Agrawal, P. N., Jindal, A., Tampi, P. S., Goyal, A., Maskey, D., et al. (2022) · Lung India · doi:10.4103/lungindia.lungindia_568_21 · Cited by 11
Cottin, V., Bonniaud, P., Cadranel, J. L., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, É., et al. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.01.014 · Cited by 14
Self-citationYang, S.-G., Yu, X., Li, J., Xie, Y., Zhang, W., Ban, C., Feng, J., Wu, L., Lu, X., Zhao, L., et al. (2022) · Trials · doi:10.1186/s13063-022-06684-0 · Cited by 9
End-of-life care for idiopathic pulmonary fibrosis patients with acute exacerbation
Akiyama, N., Fujisawa, T., Morita, T., Koyauchi, T., Matsuda, Y., Mori, M., Miyashita, M., Tachikawa, R., Tomii, K., Tomioka, H., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02204-5 · Cited by 10
Self-citationUse of a pulmosphere model to evaluate drug antifibrotic responses in interstitial lung diseases
Dsouza, K. G., Surolia, R., Kulkarni, T., Li, F. J., Singh, P., Zeng, H., Stephens, C. T., Kumar, A., Wang, Z., & Antony, V. B. (2023) · Respiratory Research · doi:10.1186/s12931-023-02404-7 · Cited by 10
Drug-Induced Thrombocytopenia Due to Nintedanib during Treatment of Idiopathic Pulmonary Fibrosis
Dumic, I., Charokopos, A., Parmar, A., et al. (2023) · Medicina · doi:10.3390/medicina59050999 · Cited by 9
“Bleeding complications during Nintedanib therapy occurred in 10% of the patients but this was not related to the thrombocytopenia that was noted in less than 1% of patients [7,8].”
BackgroundMethodResultInfluentialBattista, M. D., Tavanti, L. M., Pistelli, F., Carrozzi, L., Rio, M. D., Rossi, A., Puccetti, L., Tavoni, A. G., Romei, C., Morganti, R., et al. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01286-x · Cited by 12
“So far, the NIN safety profile has been defined using data from some clinical trials (Cottin et al. 2022; Dis-tler et al. 2019; Richeldi et al. 2014).”
BackgroundSantos, G., Fabiano, A., Mota, P. C., Rodrigues, I., Carvalho, D., Melo, N. C. V., Bastos, H. N., Alexandre, A. T., Moura, C. S., Guimarães, S., et al. (2023) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2023.102261 · Cited by 13
Therapy for idiopathic pulmonary fibrosis: lessons from pooled data analyses
Troy, L. K., & Corte, T. J. (2015) · European Respiratory Journal · doi:10.1183/13993003.01669-2015 · Cited by 9
Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF
Murray, L. A., Grainge, C., Wark, P. A. B., & Knight, D. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.003 · Cited by 12
Ouyang, J., Carroll, K. J., Koch, G. G., & Li, J. (2017) · Pharmaceutical Statistics · doi:10.1002/pst.1808 · Cited by 9
Toward Early Identification of Clinically Relevant Interstitial Lung Disease
Salisbury, M. L., & Lynch, D. A. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1235ed · Cited by 9
Combination Therapy and the Start of a New Epoch for Idiopathic Pulmonary Fibrosis?
Maher, T. M. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201709-1939ed · Cited by 9
Establishment of an indirect ELISA for detection of the novel antifibrotic peptide M10
Akter, T., Atanelishvili, I., Noguchi, A., Silver, R. M., & Bogatkevich, G. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188588 · Cited by 9
Predictors of acute exacerbation in biopsy-proven idiopathic pulmonary fibrosis
Kishaba, T., Hozumi, H., Fujisawa, T., Nei, Y., Enomoto, N., Sugiura, H., Kitani, M., & Suda, T. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.02.004 · Cited by 9
Smith, R. A., Sathananthan, M., Kaur, P., & Jeganathan, N. (2020) · Heart & Lung · doi:10.1016/j.hrtlng.2020.05.006 · Cited by 10
The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis.
Kinoshita, Y., Ishii, H., Nabeshima, K., & Watanabe, K. (2021) · PubMed · doi:10.14670/hh-18-289 · Cited by 16
Managing interstitial lung disease detected on CT during lung cancer screening
Southern, B. D., Scheraga, R. G., & Yadav, R. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83a.14157 · Cited by 9
Kim, H., Yoon, S. H., Hong, H., Hahn, S., & Goo, J. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-34230-z · Cited by 10
Huang, T., Kuo, C., Chen, C., Tseng, Y., Wu, C., & Lin, S. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01559-7 · Cited by 10
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?
Goodwin, A. T., Noble, P. W., & Tatler, A. L. (2022) · European Respiratory Journal · doi:10.1183/13993003.01748-2022 · Cited by 7
Self-citationNeutrophil extracellular traps linked to idiopathic pulmonary fibrosis severity and survivalPreprint
Matson, S. M., Ngo, L. T., Sugawara, Y., Fernando, V., Lugo, C., Azeem, I., Harrison, A., Alsup, A., Nissen, E., Koestler, D. C., et al. (2024) · medRxiv · doi:10.1101/2024.01.24.24301742 · Cited by 9
Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
Astor, T. L., Goldberg, H. J., Snyder, L. D., Courtwright, A., Hachem, R., Pena, T., Zaffiri, L., Criner, G. J., Budev, M. M., Thaniyavarn, T., et al. (2023) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666231165912 · Cited by 8
Nozawa, K., Takatsuka, D., Endo, Y., Horisawa, N., Ozaki, Y., Kataoka, A., Kotani, H., Yoshimura, A., Hattori, M., Sawaki, M., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103703 · Cited by 9
Suda, T., Kondoh, Y., Hongo, Y., Yoshida, M., Hiroi, S., Iwasaki, K., Takeshima, T., & Homma, S. A. (2022) · Respiratory Investigation · doi:10.1016/j.resinv.2022.08.004 · Cited by 10
Graph neural networks for the identification of novel inhibitors of a small RNA
Haga, C. L., Yang, X., Gheit, I. S., & Phinney, D. G. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.10.002 · Cited by 10
“Although pirfenidone [4] and nintedanib [5] are approved drugs that can slow disease progression, a significant proportion (18–32”
Lee, H., Jeong, O.-Y., Park, H. J., Lee, S., Bok, E., Kim, M., Suh, Y. S., Cheon, Y., Kim, H. O., Kim, S., et al. (2023) · Immune Network · doi:10.4110/in.2023.23.e45 · Cited by 8
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?
Tsoyi, K., & Rosas, I. O. (2024) · European Respiratory Journal · doi:10.1183/13993003.02188-2023 · Cited by 8
Barth, S. E., Edwards, C. C., Saini, G., Haider, Y., Williams, N., Storrar, W., Jenkins, G. R., Stewart, I. D., & Wickremasinghe, M. I. Y. (2024) · Respiratory Research · doi:10.1186/s12931-024-02787-1 · Cited by 15
Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
Liu, J., Wang, F., Hong, Y., & Luo, F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29266 · Cited by 8
“The applications of pirfenidone and nintedanib succeeded in alleviating the impaired lung capacity [10 – 14], providing therapeutic anticipation against pulmonary fibrosis.”
BackgroundWong, S. L., Gan, J. S., Rubis, G. D., Paudel, K. R., Yeung, S., Chellappan, D. K., Keng, P. S., & Dua, K. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105942 · Cited by 9
“INPULSIS phase 3 trials I and II demonstrated a noteworthy reduction in the FVC deterioration rate among PF patients, although the death rate stayed constant [61].”
MethodEffect of Antifibrotic Use on Mortality in Patients with Idiopathic Pulmonary Fibrosis
Xu, H., Hui, S. L., Lee, J. S., Zhang, Z., & Boente, R. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202312-1054oc · Cited by 10
Kabul, E. G., Demır, P., BALKIŞLI, B. Ç., Ulutaş, F., Yenil, S., Çalık, B. B., & Çobankara, V. (2024) · Thoracic research and practice · doi:10.5152/thoracrespract.2024.23135 · Cited by 13
Pharmacological Treatment of Interstitial Lung Diseases: A Novel Landscape for Inhaled Agents
D’Agnano, V., Perrotta, F., Fomez, R., Carrozzo, V. M., Schiattarella, A., Zamparelli, S. S., Pagliaro, R., Bianco, A., & Mariniello, D. F. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111391 · Cited by 12
“The recommended full oral dose is 150 mg, twice per day, or 100 mg twice per day in patients who do not tolerate the full dose or with mild hepatic impairment [11,12].”
Aggarwal, R., Oddis, C. V., Sullivan, D. I., Moghadam‐Kia, S., Saygın, D., Kass, D. J., Koontz, D. C., Li, P., Conoscenti, C., Olson, A. L., et al. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03314-0 · Cited by 15
Takada, T., Aoki, A., Shima, K., & Kikuchi, T. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.11.003 · Cited by 9
Fibroblast Heterogeneity in Inflammatory Bowel Disease
Ke, B.-J., Dragoni, G., & Matteoli, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313008 · Cited by 9
Hermann, R., Grobost, V., Horn, X. L. G., Lavigne, C., Parrot, A., Rivière, S., Seguier, J., Fargeton, A., de-Montigny, A., Huot, M., et al. (2024) · Angiogenesis · doi:10.1007/s10456-024-09962-4 · Cited by 10
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.